Patriot Financial Group Insurance Agency LLC Purchases 903 Shares of GSK plc (NYSE:GSK)

Patriot Financial Group Insurance Agency LLC boosted its position in GSK plc (NYSE:GSK) by 5.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,408 shares of the pharmaceutical company’s stock after buying an additional 903 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in GSK were worth $671,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. 1832 Asset Management L.P. lifted its position in shares of GSK by 9.1% in the first quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock worth $132,000 after purchasing an additional 257 shares in the last quarter. Boltwood Capital Management lifted its position in GSK by 2.5% during the 2nd quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company’s stock worth $429,000 after buying an additional 270 shares in the last quarter. J.W. Cole Advisors Inc. boosted its stake in shares of GSK by 4.7% during the 1st quarter. J.W. Cole Advisors Inc. now owns 6,097 shares of the pharmaceutical company’s stock worth $261,000 after buying an additional 271 shares during the last quarter. First Affirmative Financial Network grew its holdings in shares of GSK by 4.7% in the 2nd quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company’s stock valued at $245,000 after acquiring an additional 283 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of GSK by 9.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock worth $137,000 after purchasing an additional 303 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Up 1.0 %

Shares of GSK opened at $37.90 on Tuesday. The company has a current ratio of 0.82, a quick ratio of 0.54 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $78.54 billion, a PE ratio of 13.73, a P/E/G ratio of 1.23 and a beta of 0.65. The firm’s 50 day moving average is $41.05 and its 200-day moving average is $41.13. GSK plc has a 12 month low of $33.67 and a 12 month high of $45.92.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.09. The firm had revenue of $9.95 billion during the quarter, compared to analysts’ expectations of $9.49 billion. GSK had a return on equity of 51.48% and a net margin of 12.87%. Equities research analysts forecast that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Investors of record on Friday, August 16th were given a dividend of $0.3843 per share. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, August 16th. This represents a $1.54 annualized dividend and a yield of 4.06%. GSK’s dividend payout ratio is currently 55.80%.

Insiders Place Their Bets

In other news, major shareholder Plc Gsk bought 2,791,930 shares of the company’s stock in a transaction dated Friday, September 27th. The stock was bought at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the transaction, the insider now owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on GSK shares. Jefferies Financial Group raised their target price on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. UBS Group downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Argus raised GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Barclays raised GSK to a “hold” rating in a report on Tuesday, August 27th. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, GSK presently has a consensus rating of “Buy” and a consensus price target of $50.00.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.